CHA Bio Group said it would attend the 2024 BIO International Convention, the world's largest bio exhibition, from June 3 to 6 in San Diego, California.

This year, the company has expanded to two booths. Matica Biotechnology, a U.S.-based CGT (cell and gene therapy) CDMO CHA Biotech, has acquired, and CHA Bio Group will run their booths independently.

Matica Biotechnology's booth will be in the exhibition hall, where Korean and international CDMOs will be present. In 2022, it was the first Korean company to build a CGT CDMO facility in Texas and developed the cell line MatiMax in 2023.

In addition, the company is expanding its business to Asia and North America with five production facilities -- Matica Biotechnology in the U.S., CHA University Bundang Medical Center GMP in Korea, Matica Biolabs, Cell Gene Biobank (CGB), and Matica Bio Japan.

During the event, Matica Bio will showcase these competitive advantages to customers and potential customers.

The Biosecure Act, a recent initiative by the U.S. government, calls for biopharmaceuticals to be produced in the U.S. Matica Bio plans to actively pursue orders, leveraging its CGT CDMO facility in the U.S. During the event, it plans to meet with more than 30 customers and potential customers.

At the CHA Bio Group booth, CHA Biotech, CMG Pharmaceutical, and CHA Vaccine Research Institute will actively promote their core pipelines and discuss technology transfer and joint development. The booth will be located among many global pavilions, including North America, and will be actively engaged in business partnerships.

CHA Biotech will actively promote the development status of cell therapy drugs, including “CBT101,” an anticancer immune cell therapy drug based on NK cells, and “CordSTEM-DD,” a stem cell therapy drug. To maximize the effectiveness and characteristics of NK cell therapies, it is developing CAR-NK cell therapies that apply chimeric antigen receptor (CAR) and various combination therapies such as immuno-oncology drugs and antibodies, according to CHA Bio Group.

CHA Vaccine Research Institute plans to actively conduct partnership meetings with global big pharma and biotech companies. In addition to technology transfer and joint development of hepatitis B vaccine and shingles vaccine using independently developed immune enhancers, the institute will also discuss newly developed immune anticancer drugs to expand its research area into anticancer drugs.

CMG Pharmaceutical will present its oral disintegration film (ODF) product based on STARFILM technology. In addition to Depipzo, the world's first ODF formulation of an antipsychotic drug, which is seeking U.S. FDA approval in 2025, the company will conduct sales activities for the export of Narafil ODF, the world's first ODF-type migraine drug, and Jeterofil, an erectile dysfunction drug.

"The overall business environment of the bio-industry is improving as overseas biotech companies are expanding their R&D investments," CHA Biotech CEO Oh Sang-hoon said. "We will introduce CHA Biotech's cell therapy technology and CDMO competitiveness at BIO 2024 in the U.S. and explore the global market."